Key Takeaway
In 200 postmenopausal women, 1000 mg/day royal jelly for 8 weeks significantly reduced overall menopausal symptom scores versus placebo.
Summary
Double-blind, randomized placebo-controlled clinical trial conducted in Bandar Abbas, Iran, enrolling 200 postmenopausal women aged 45-60. Participants received either 1000 mg/day of royal jelly capsules or placebo for 8 weeks. The primary outcome was menopausal symptom score measured by the Menopause Rating Scale.
Baseline scores did not differ between groups. After 8 weeks, mean menopausal symptom scores decreased significantly in the royal jelly group but not in the placebo group, with a statistically significant between-group difference favoring royal jelly. Improvements spanned somatic, psychological, and urogenital domains.
This is one of the larger RCTs of royal jelly for menopause. It strengthens the evidence base for a meaningful symptomatic effect of 1 g/day over two months and is a core reference in subsequent meta-analyses of royal jelly for postmenopausal symptoms.